aTYR PHARMA INC — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
aTyr Pharma and Kyorin Pharmaceutical terminated their January 2020 Collaboration and License Agreement effective July 30, 2026, following Kyorin's termination notice on May 12, 2026. Under the termination agreement, aTyr regains worldwide, irrevocable, perpetual, royalty-free, exclusive licenses to all New Kyorin IP and Kyorin Background Technology for the reversion products (including efzofitimod/KRP-R120). Kyorin transfers all clinical data, regulatory filings, and the orphan drug designation to aTyr, with Kyorin bearing archival storage costs during regulatory retention periods.
Why this rating
Regaining full IP control and clinical data for lead program is strategically significant for a ~$464M biotech; eliminates ongoing royalty obligations and restores development autonomy, though termination suggests prior collaboration underperformed.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.